股东大会议事规则 上海复旦张江生物医药股份有限公司 股东大会议事规则 （2024年6月27日股东大会通过） 第一章 总则 （二） 选举和更换非由职工代表担任的董事，决定有关董事的报酬事项； 1 （三） 选举和更换非由职工代表担任的监事，决定有关监事的报酬事项； （四） 审议批准董事会的报告； （五） 审议批准监事会的报告； 第一条 为了进一步规范上海复旦张江生物医药股份有限公司（以下称"公 司"）股东大会的议事方式和决策程序，促使股东和股东大会有效地履行其职责， 提高股东大会规范运作和科学决策水平，根据《中华人民共和国公司法》（以下 称"《公司法》"）、《中华人民共和国证券法》《上市公司治理准则》《科创 板上市公司持续监管办法（试行）》《上市公司股东大会规则》《上海证券交易 所科创板股票上市规则》和《香港联合交易所有限公司证券上市规则》（以下合 称"上市规则"）、其他有关法律、行政法规、部门规章、规范性文件（以下合 称"法律法规"）及《上海复旦张江生物医药股份有限公司章程》（以下称"《公 司章程》"）的规定，并结合公司的实际情况，制订本议事规则（以下称"本规 则"）。 第二条 本规则自生效之日起，即对股东大会 ...

监事会议事规则 第一条 为完善法人治理结构，促进上海复旦张江生物医药股份有限公司 （以下称"公司"）规范运作，维护公司、股东、债权人合法权益，规范公司监 事会的组织和行为，确保公司监事会能够依法独立行使职权，根据《中华人民共 和国公司法》（以下称"《公司法》"）、《中华人民共和国证券法》《上海证券交易 所科创板股票上市规则》和《香港联合交易所有限公司证券上市规则》（以下合 称"上市规则"）以及《上海复旦张江生物医药股份有限公司章程》（以下称"《公 司章程》"），制定本议事规则（以下称"本规则"）。本规则应同时遵守《上海证 券交易所科创板股票上市规则》和《香港联合交易所有限公司证券上市规则》的 相关规定，如两个上市规则规定不一致时，按从严原则执行。 第二条 本规则自生效之日起，即成为对公司监事会的召集、召开、议事及 表决程序具有约束力的法律文件。 第三条 监事会代表全体股东对公司的经营管理活动以及董事会、高级管理 人员实施监督，监事会向股东大会负责。 第四条 监事会应严格遵守《公司法》及其他法律、法规关于监事会的各项 规定，认真组织好监事会工作，履行监事会职责，维护公司利益，尤其要关注并 监督股东的合法权益不受 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 获得补助的基本情况 上海复旦张江生物医药股份有限公司（以下简称"公司"）子公司泰州复旦张 江药业有限公司（以下简称"泰州复旦张江"）于近日收到政府补助资金人民币 1,000 万元。自 2024 年初至本公告披露日，泰州复旦张江累计收到政府补助资金 共计人民币 1,620 万元，为与收益相关的政府补助。 股票代码：688505 股票简称：复旦张江 编号：临 2024-018 上海复旦张江生物医药股份有限公司 关于获得政府补助的公告 特此公告。 上海复旦张江生物医药股份有限公司 董 事 会 二〇二四年六月十八日 1 二、 补助的类型及对公司的影响 根据《企业会计准则第16号——政府补助》等有关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助数据未经审计，具体的会计处 理以及对公司损益的影响，最终以审计机构年度审计确认后的结果为准。敬请投 资者注意投资风险。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 於二零二四年六月三日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 III，同意以日常營 運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 上市規則的涵義 茲提述本公司於二零二四年四月二十二日披露之公告，內容有關本公司認購浦發銀行結構性存款 產品。如该公告披露，於二零二四年四月一日及於二零二四年四月二十二日，本公司與浦發銀行 分別訂立浦發銀行結構性存款產品協議 I 及浦發銀行結構性存款產品協議 II，同意以日常營運產 生的自有閑置資金向浦發銀行認購總金額為人民幣 2.00 億元的結構性存款產品。浦發銀行結構性 存款產品協議 II 已於二零二四年五月二十二日到期兌付。 根據上市規則第 14.22 條，浦發銀行結構性存款產品協議項下的交易需合併計算。鑒於與浦發銀 行訂立浦發銀行結構性存款產品協議 I 項下的結構性 ...

Financial Performance - The net profit attributable to shareholders of the listed company decreased by 73.29% due to the termination of cooperation with a promotional service provider[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 292.19%, significantly impacting revenue from a key product during the reporting period[4]. - The basic and diluted earnings per share both dropped to 0.00 yuan, reflecting a 100% decline compared to the previous period[4]. - The total profit for the period was 1,329,266 yuan, down from 2,173,031 yuan in the previous year[19]. - The net profit for the period was 2,259,878 yuan, compared to 8,794,123 yuan in the same period last year[19]. - Total operating revenue for Q1 2024 was 147,647,109, a decrease of 21.94% compared to Q1 2023[38]. - Net profit attributable to shareholders for Q1 2024 was 2,347,396, down 73.29% year-over-year[38]. - Basic and diluted earnings per share for Q1 2024 were both 0.00, a decrease of 100% compared to the previous year[38]. Cash Flow and Assets - The net cash flow from operating activities improved to 43.94 million yuan, a recovery from a negative 160.26 million yuan in the same period last year[7]. - Cash and cash equivalents at the end of Q1 2024 were 1,233,394,449, compared to 888,009,829 at the end of Q1 2023[22]. - The net cash flow from investing activities was -3,807,572 for Q1 2024, a significant improvement from -235,735,353 in Q1 2023[22]. - Cash inflow from operating activities totaled 244,729,122 in Q1 2024, compared to 162,901,241 in Q1 2023, showing strong operational performance[27]. - The total assets decreased to 2,825,346,356 yuan from 2,876,687,507 yuan[16]. - The total non-current assets amounted to 992,027,577 yuan, down from 1,007,262,621 yuan[16]. - Total liabilities decreased from 518,124,139 to 464,492,233, a reduction of approximately 10.4%[59]. - Total current liabilities decreased from 505,018,842 to 453,049,327, a reduction of about 10.3%[59]. Research and Development - Research and development expenses increased to 63,616,910 in Q1 2024 from 54,123,028 in Q1 2023, reflecting a focus on innovation[25]. - R&D investment totaled RMB 64,173,693, representing 43.46% of operating income, an increase of 14.64 percentage points from the previous year[50]. Equity and Liabilities - The equity attributable to shareholders of the listed company was RMB 2,359,932,124, showing a slight increase of 0.10% compared to the end of the previous year[50]. - Total equity increased from 2,358,563,368 to 2,360,854,123, a slight increase of approximately 0.1%[59]. - The company's retained earnings rose from 918,311,622 to 920,659,018, an increase of approximately 0.3%[59]. - Non-current liabilities decreased from 13,105,297 to 11,442,906, representing a decline of about 12.7%[59]. - The company's lease liabilities decreased from 10,952,722 to 9,869,581, a reduction of about 9.9%[59]. Revenue and Sales Strategy - The company reported a significant decline in revenue for 2023 due to underperformance in the sales of its product, Libao Duo®, leading to a notable decrease in overall income compared to the previous year[45]. - The company is in discussions to terminate its marketing cooperation with Shanghai Huizheng, aiming to improve the sales strategy for Libao Duo®[45]. - The company plans to leverage various bidding and procurement opportunities to enhance its marketing efforts through specialized CSO companies in different provinces[45]. Other Financial Metrics - The fair value changes of financial assets and liabilities resulted in a gain of 4,554,032 yuan, primarily from interest or returns on structured deposits and wealth management products[3]. - The weighted average return on net assets decreased by 0.29 percentage points to 0.10%[50]. - Accounts receivable decreased to RMB 452,005,745 from RMB 446,223,107, indicating a slight increase in collection efficiency[57]. - The company's deferred income decreased from 2,152,575 to 1,573,325, a decline of approximately 26.8%[59]. - Minority interests decreased from 1,009,517 to 921,999, a decrease of about 8.6%[59].

些华永道 上海复旦张江生物医药股份有限公司董事会: 普华永道中天会计师事务所(特殊普通合伙)(以下简称"我们"或"普华永道")接受上 海复旦张江生物医药股份有限公司(以下简称"复旦张江")委托,审计了复旦张江 2023 年 12月 31 日的合并及公司资产负债表、2023年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表和财务报表附注(以下合称"2023年度财务报 表")。我们按照中国注册会计师审计准则的规定执行了审计工作,于 2024年 3月 28 日出具了报告号为普华永道中天审字(2023)第 10115 号的无保留意见的审计报告。 按照企业会计准则的规定编制复目张江财务报表是复旦张江管理层的责任。我们的 责任是在实施审计工作的基础上对复旦张江财务报表发表审计意见。 我们阅读了上海证券交易所向复旦张江出具的《关于上海复旦张江生物医药股份有 限公司 2023 年年度报告的信息披露监管问询函》(上证科创公函【2024】0053 号)(以 下简称"2023年年报问询函"),我们以上述我们对 2023 年度财务报表所执行的审计工 作为依据,对复旦张江就 2023年年报问询函中需由年审会计师发 ...

Revenue and Profitability - Revenue for the first quarter was RMB 147,647,109, representing a decrease of 21.94% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 73.29% to RMB 2,347,396[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB -4,515,799, a decline of 292.19%[2] - The company's total operating revenue for Q1 2024 was RMB 147,647,109, a decrease of 22% compared to RMB 189,147,552 in Q1 2023[13] - Operating profit for Q1 2024 was RMB 1,190,039, down from RMB 3,481,590 in Q1 2023, reflecting a significant decline in profitability[13] - The net profit attributable to shareholders for Q1 2024 was RMB 2,347,396, compared to RMB 8,787,158 in the same period last year, indicating a decrease of approximately 73%[13] Research and Development - Research and development expenses totaled RMB 64,173,693, an increase of 17.73% year-on-year[2] - R&D expenses accounted for 43.46% of revenue, up by 14.64 percentage points from the previous year[2] - Research and development expenses for Q1 2024 were RMB 63,616,910, an increase from RMB 54,123,028 in Q1 2023, indicating a focus on innovation despite declining revenues[13] Cash Flow and Liquidity - The net cash flow from operating activities was RMB 43,938,388, a significant improvement from RMB -16,026,020 in the same period last year[5] - In Q1 2024, cash inflow from operating activities was RMB 244,729,122, a 50.0% increase from RMB 162,901,241 in Q1 2023[14] - The net cash flow from operating activities was RMB 43,938,388, compared to a negative RMB 160,260,214 in the same period last year[14] - Cash outflow for purchasing goods and services decreased significantly to RMB 82,458,828 from RMB 228,636,546, marking a 64.0% reduction[14] - The net increase in cash and cash equivalents for the quarter was RMB 37,498,452, compared to a decrease of RMB 401,292,835 in Q1 2023[14] - The ending balance of cash and cash equivalents was RMB 1,233,394,449, up from RMB 888,009,829 in the previous year[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,825,346,356, a decrease of 1.78% from the end of the previous year[2] - Total current assets decreased to RMB 1,833,318,779 from RMB 1,869,424,886, reflecting a decline of about 2%[11] - Total liabilities decreased to RMB 464,492,233 as of March 31, 2024, down from RMB 518,124,139 at the end of 2023, representing a reduction of approximately 10%[12] - Equity attributable to shareholders increased slightly by 0.10% to RMB 2,359,932,124[2] Strategic Changes - The company terminated its cooperation with a promotional service provider, impacting sales revenue of a key product during the reporting period[5] - The company plans to terminate its marketing cooperation with Shanghai Huizheng due to underperformance of its product, Liboduo, which has led to a significant drop in revenue[10] - The company is adjusting its sales strategy for Liboduo by selecting specialized CSO companies for regional marketing and academic promotion to enhance communication efficiency and reduce operational risks[10] - The company aims to leverage various bidding and procurement opportunities to enhance its market presence and adapt its promotional strategies to local conditions[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,860[8] Cash Flow from Investments - Cash inflow from investment activities was RMB 919,724,441, down 13.0% from RMB 1,055,510,659 in Q1 2023[14] - The net cash flow from investment activities was negative RMB 3,807,572, an improvement from negative RMB 235,735,353 year-over-year[14] Financing Activities - Cash outflow related to financing activities decreased to RMB 2,669,076 from RMB 5,251,044, a reduction of 49.2%[14] Accounting Standards - The company has not applied new accounting standards or interpretations for the first quarter of 2024[15]

Financial Performance - The company's revenue for 2023 was RMB 850.733 million, a decrease of 17.5% compared to RMB 1,031.160 million in 2022[11]. - The profit before tax for 2023 was RMB 97.528 million, down from RMB 132.294 million in the previous year, representing a decline of 26.2%[11]. - The total comprehensive income attributable to shareholders for 2023 was RMB 107.970 million, a decrease of 21.1% from RMB 136.847 million in 2022[11]. - Basic and diluted earnings per share attributable to shareholders for 2023 were RMB 0.1051, down from RMB 0.1340 in 2022, a decline of 21.7%[11]. - The company reported a total comprehensive income of RMB 107.793 million for the year, compared to RMB 136.122 million in 2022, indicating a decrease of 21.0%[11]. - Net profit for 2023 was approximately RMB 108,450 thousand, a decline of about 21% from RMB 137,272 thousand in 2022, with a stable net profit margin of 13%[51]. - The profit attributable to shareholders for 2023 was RMB 108,627 thousand, down 21% from RMB 137,997 thousand in 2022[52]. - The group's operating revenue decreased by 17.50% year-on-year due to underperformance in sales of the main product, Ribavirin®[31]. - The sales of Libao Duo® did not meet expectations, leading to a decline in overall revenue and affecting other financial metrics[81]. Assets and Liabilities - Total assets as of December 31, 2023, were RMB 2,876.688 million, a slight decrease from RMB 2,976.007 million in 2022[12]. - The company's total liabilities decreased to RMB 518.124 million in 2023 from RMB 722.986 million in 2022, reflecting a reduction of 28.3%[12]. - As of December 31, 2023, the company's long-term equity investment net value was RMB 287,518 thousand, with an investment loss of approximately RMB 23,540 thousand during the reporting period[53]. - As of December 31, 2023, the company had cash and cash equivalents of approximately RMB 1,195,896 thousand, down from RMB 1,289,303 thousand as of December 31, 2022[58]. Research and Development - The company has been focusing on research and development of new technologies to strengthen its competitive position in the biopharmaceutical sector[14]. - The company focuses on innovative research and development in biomedicine, with a strategic emphasis on photodynamic therapy (PDT) and antibody-drug conjugates (ADC) for various diseases[15]. - The company has developed a pipeline of photodynamic drugs targeting conditions such as cervical cancer, breast cancer, and glioma, with ongoing clinical trials for new indications[17]. - The company aims to leverage its competitive advantages in photodynamic technology to strengthen its market position and expand its product offerings[15]. - The company is committed to balancing innovation with industrialization, focusing on both research and market development to ensure sustainable growth[16]. - The company has established multiple technology platforms, including gene engineering and nanotechnology, to support its drug development initiatives[15]. - The company emphasizes the importance of clinical unmet needs in guiding its research and development efforts for photodynamic drugs[17]. - The company is actively pursuing collaborations to accelerate its growth and achieve a stable position in the market[15]. - The company is focused on expanding its ADC drug portfolio and enhancing its R&D capabilities in biopharmaceuticals and small molecules[26]. Clinical Trials and Product Development - The company submitted three clinical trial applications for intraoperative molecular imaging (IMI) technology, aimed at enhancing tumor visualization during surgeries for glioma, bladder cancer, and breast cancer[18]. - The combination of ALA and photodynamic therapy for the treatment of HPV-related cervical precancerous lesions has completed Phase II clinical trials and will soon initiate Phase III trials[19]. - The Phase II clinical trial for ALA photodynamic therapy in treating moderate to severe acne has been completed, with ongoing research into pain-free treatment options[19]. - The application for Phase II clinical trials of ALA granules for intraoperative visualization in breast cancer surgery has been accepted, addressing a significant clinical need in real-time tumor margin assessment[21]. - The application for verification clinical trials of ALA granules for non-muscle invasive bladder cancer surgery has been accepted, aiming to improve tumor detection rates during TURBT procedures[21]. - The application for verification clinical trials of ALA oral solution for visualization in high-grade glioma surgery has been accepted, focusing on enhancing surgical outcomes and patient survival[21]. - The photodynamic drug Revamed (Heimofen injection) is undergoing Phase II clinical trials in the U.S., with expectations for significant clinical benefits upon successful market entry[22]. - The company has completed bioequivalence clinical studies and confirmatory clinical trials for the obeticholic acid project, which targets primary biliary cholangitis (PBC), and will soon apply for production registration[28]. - The company has initiated Phase II clinical studies for the drug FZJ-003 targeting atopic dermatitis and ulcerative colitis, demonstrating its commitment to advancing its pipeline[30]. Market Strategy and Expansion - The company aims to enhance its market expansion strategies and invest in new product development to drive future growth[14]. - The company is actively seeking to expand its presence in international markets to enhance its competitiveness amid ongoing industry reforms and changes in domestic policies[39]. - The company is experiencing a shift in the pharmaceutical industry towards innovation, with a notable increase in investment in R&D for new drugs[39]. - The company is focused on international registration of existing products to enhance treatment value and commercial benefits[31]. - The company plans to terminate the marketing service agreement with Shanghai Huizheng effective December 31, 2023, due to underperformance of the product Liboduo®[43]. Corporate Governance - The company emphasizes a commitment to robust corporate governance to enhance transparency and accountability, thereby protecting shareholder interests[131]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, has reviewed the financial statements and internal controls for the fiscal year 2023[154]. - The independent non-executive directors have confirmed their independence, aligning with regulatory requirements[156]. - The company has established a comprehensive corporate governance code, including rules for various committees and information disclosure systems[178]. - The board consists of two executive directors, two non-executive directors, and three independent non-executive directors, with a total of seven members[180]. Shareholder Information - The proposed final dividend for the year ending December 31, 2023, is RMB 0.07 per share, totaling RMB 72,560,047 (including tax) based on the current issued share capital of 1,036,572,100 shares[119]. - The net profit attributable to ordinary shareholders for 2023 is RMB 108,627,368, resulting in a dividend payout ratio of 66.80%[123]. - The company has maintained a consistent dividend of RMB 0.07 per share over the past three years, with total cash dividends of RMB 72,560,047 in both 2023 and 2022[123]. - Major shareholders include Shanghai Pharmaceuticals with 20.27% of total issued shares and New Venture II with 15.14%[145]. - The top ten shareholders hold a total of 1,037,000,000 shares, representing 102.70% of the total issued shares, indicating significant concentration[146].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 於二零二四年四月一日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 I，同意以日常營 運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 於二零二四年四月二十二日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 II，同意以日常 營運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 浦發銀行結構性存款產品協議 於二零二四年四月二十二日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議 II，同意以日 常營運產生的自有閑置資金向浦發銀行認購總金額為人民幣 1.00 億元的結構性存款產品。 上市規則的涵義 就浦發銀行結構性存款產品協議 I 項下產品的認購金額而言，其適用百分比率（定義見上市規則 第 14.07 條）低於 5%，故根據上市規則第 14 章，该交易不構成本公司之須予披露的交 ...

股票代码：688505 公司简称：复旦张江 编号：2024-001 上海复旦张江生物医药股份有限公司 投资者关系活动记录表 （2024 年 4 月 17 日） 上海复旦张江生物医药股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 ...